Lymphoma is the third most common cancer in children p15 years of age. The prognosis for children with newly diagnosed chemosensitive non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) has improved significantly. However, in children with relapsed and refractory NHL, the prognosis is not as promising and the best treatment approach for this poor risk group continues to be a challenge. Between 25 and 30% of patients with advanced stage HD still relapse and in subsets of this group, the outcome is dismal. Aggressive chemotherapy followed by autologous bone marrow transplantation has been used with some improvement in survival. Some centers have investigated allogeneic stem cell transplantation in pediatric patients with recurrent/relapsed lymphoma. There is little consistency in therapeutic approaches and there is no formal recommendation on the best approach for this poor prognostic subgroup. We illustrate the reported pediatric experience of transplantation for lymphoma and discuss how the results from these trials are influencing how we approach the treatment in certain subgroups of pediatric patients with relapsed/ refractory lymphoma.
Introduction
The third most common cancer in children p15 years of age is lymphoma. It accounts for the largest proportion (20% of all cases) of invasive cancers with Hodgkin's disease (HD) responsible for 12% and non-Hodgkin's lymphoma (NHL) for 7% of cancer diagnosed in 15-to 30-year olds (adolescent/young adults). 1, 2 Childhood NHL, commonly classified as intermediate (30%) and high grade (70%) disease, 3, 4 is classified into four major subtypes of childhood NHL, Burkitt's lymphoma (BL), lymphoblastic lymphoma (LL), diffuse large B-cell lymphoma and anaplastic large cell lymphoma (ALCL). [5] [6] [7] The Revised European-American Classification of Lymphoid Neoplasms defines major histologic subtypes of HD: nodular lymphocyte predominant, and classical HD whose subtypes include lymphocyte rich, nodular sclerosing, mixed cellularity, lymphocyte depleted and ALCL Hodgkin's-like. 8 HD in children is not biologically different compared to adults; however, mixed cellularity, nodular lymphocyte predominant and nodular sclerosing are the subtypes more commonly seen in children.
The prognosis for children with relapsed and refractory HD and NHL is not as promising as it is for newly diagnosed patients, and the optimal treatment approach for this poor prognostic group continues to be a challenge. It has been fairly well established by randomized studies that (1) in advanced HD consolidation with autologous stem cell transplantation (AutoSCT) compared to conventional chemotherapy as part of upfront therapy does not result in improved survival; (2) there is a benefit of AutoSCT over conventional chemotherapy in the relapsed setting for both NHL and HD and (3) the need to develop a risk stratified treatment approach for pediatric patients with high-risk NHL and HD. Controversies include (1) AutoSCT as upfront consolidation for certain groups of high-risk NHL, (2) what to do with chemotherapy-resistant patients and (3) allogeneic stem cell transplantation (AlloSCT) vs AutoSCT for some subgroups of NHL and HD where an alloGvL effect has been demonstrated.
Clinical presentation

NHL
Approximately 70% of children with NHL present with advanced disease and/or have metastatic involvement, including BM, central nervous system and/or bone. 1, 3, 9 The primary therapy for childhood NHL is multiagent chemotherapy, and the intensity and length of therapy are usually determined by the subtype and stage of disease. The prognosis for children with NHL, both limited and advanced stage disease, has improved significantly over the past two decades. Children with limited stage NHL have an excellent prognosis with an estimated 5-year event-free survival (EFS) of 90-95%. [10] [11] [12] [13] The prognosis for advanced stage disease has also improved and varies based on subtype (60-90% 5-year EFS).
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HD
Patients with HD commonly present with cervical or supraclavicular lymphadenopathy and most will present with some degree of mediastinal involvement. Current treatment involves the use of combined chemotherapy with or without low-dose involved field radiation therapy. Treatment is largely determined by disease stage, patient's age at diagnosis, the presence or absence of 'B' symptoms, the presence of hilar lymphadenopathy and/or bulky nodal disease and the rapidity of response to therapy. With current therapy, the long-term disease-free survival (DFS) in both children and adults with newly diagnosed localized and advanced stage HD ranges between 85-100 and 70-90%, respectively. 23 However, 25-30% of patients with advanced stage HD still relapse and in subsets of patients the outcome is dismal. 24, 25 Stem cell transplantation for childhood NHL In children with relapsed or refractory NHL, the prognosis is not as promising and the best treatment approach for this poor risk group continues to be a challenge. [26] [27] [28] Aggressive chemotherapy followed by autologous BMT has been used with some improvement in survival. [29] [30] [31] [32] [33] Some centers have investigated AlloSCT in pediatric patients with relapsed/ refractory NHL. [34] [35] [36] [37] There is little consistency in therapeutic approaches and there is no formal recommendation on the best approach for this poor prognostic subgroup (Table 1) .
When to do stem cell transplantation? Some data indicate that stem cell transplantation (SCT) should be considered as upfront therapy in patients with poor prognostic features and have little chance of cure with standard chemotherapy alone. 38, 42 Poor prognostic features have been defined as (1) a delayed or partial response to first-line therapy, 13, 22, 43 (2) central nervous system or BM involvement at presentation 35 or (3) time to relapse from initial diagnosis. 44 Bureo et al. 35 reported an expected EFS of 82.5% in a small group (n ¼ 13) of high-risk patients with these poor prognostic features who were consolidated with high-dose therapy followed by AutoSCT in CR1 (Table 1) . The European Group for Blood and Marrow Transplantation (EBMT), also in a retrospective review of adult and pediatric patients with ALCL, point out that those patients transplanted in CR1 had improved survival compared to those patients who received AutoSCT in CR2, partial response or sensitive relapse. 41 Although this study was not randomized to compare conventional chemotherapy vs AutoSCT as consolidation for patients with ALCL it does lead one to speculate whether this approach should be considered for certain patients with this histology.
Most pediatric SCT programs will reserve SCT in children with NHL to be used after the first relapse, progression or induction failure. High-dose therapy followed by AutoSCT has historically been and remains the standard approach for pediatric patients with chemosensitive relapse or primary refractory NHL. Won et al. 32 reported an estimated 2-year overall survival (OS) of 62.8±9.1% and EFS of 59.1±9.3% in 33 pediatric patients with relapsed (n ¼ 16) or refractory (n ¼ 17) NHL following high-dose therapy and AutoSCT compared to an EFS of 16.3±4.6% in those who received conventional chemotherapy (Table 1 ). However, this study was not randomized and the decision of AutoSCT vs conventional chemotherapy was left to institutional preference. Bureo et al. 35 reported an EFS of 68% in children with NHL following high-dose therapy and AutoSCT in CR2 (Table 1 ). Kobrinsky (CCG) et al. 39 reported no difference between chemotherapy and AutoSCT in children with chemosensitive disease (Table 1) . It is also however, difficult to draw any conclusion from this latter study since it was not designed to randomize patients between chemotherapy vs SCT and was left to physician preference.
Chemoresponse A controversy also continues concerning patients with refractory disease. Chemoresponse is another important prognostic indicator, and chemosensitive disease is considered by many in the field as an essential criterion for undergoing high-dose therapy and AutoSCT. 29 Many groups have demonstrated that patients with chemoresistant disease do not benefit from AutoSCT. 29, 33, 38 Chemoresponse may not be the only factor influencing outcome, with more aggressive upfront therapy the current standard treatment of high-dose chemotherapy followed by AutoSCT may not be the best approach for all patients. High-dose therapy and AutoSCT induces a response in many patients, but a long-term cure is not easy to achieve. Loiseau et al. 29 reported a response rate of 70% but a DFS of only 33% in 24 pediatric patients with relapsed/ refractory BL type or T-cell LL who received a high-dose busulfan conditioning regimen followed by AutoSCT (Table 1) . With the continued improvement of conventional frontline therapy, this approach will continue to become more problematic as the candidates who relapse and are referred for SCT present with more resistant and difficult to treat disease. Histology may also play a role in response in children and adolescents with relapsed/refractory NHL.
LL
Won et al.
32 demonstrated that patients with relapsed BL and diffuse large B-cell lymphoma had a better survival following high-dose therapy and AutoSCT compared to patients with relapsed LL. This compares with results reported by Levine et al. 40 showing that pediatric patients with relapsed LL had a survival of 39% following highdose therapy and AutoSCT, whereas the French group reported only one of eight patients with LL who were treated with high-dose therapy and AutoSCT was a longterm survivor (Table 1) . 29 These results are disappointing for children and adolescents with this histological subtype and clearly demonstrate that a new approach is needed for this high-risk group of patients.
B-cell lymphoma
Philip et al. 27 reported a dismal prognosis for those patients with B-cell NHL who relapsed after high-dose chemotherapy and AutoSCT (LMB-84) (Figure 1 ). The EBMT reported on one of the largest series of 89 pediatric patients with poor risk B-cell lymphoma who underwent high-dose chemotherapy followed by AutoSCT. The major factor determining survival in this study was the remission status of patients before AutoSCT. 33 They report a 5-year EFS of 48.7% for patients with chemosensitive relapse but a dismal outcome for patients with primary refractory disease, all of whom died within 1 year post transplant, with a 5-year EFS of only 8% (Table 1) . 33 
ALCL
In children and adolescents with relapsed/refractory ALCL, many groups have taken different therapeutic approaches. The prognosis for children who develop progressive or recurrent disease is poor with o50% DFS. 44 The EBMT reported their results of AutoSCT in 64 adult and pediatric patients with T-and null-cell CD30 þ ALCL (Table 1) . 41 In this series, the group who consistently benefited from high-dose therapy and AutoSCT were the patients with poor prognostic features who were The Berlin-Frankfurt-Mu¨nster (BFM) group recently reported on the feasibility and efficacy of intensive reinduction therapy followed by AutoSCT or AlloSCT in children and adolescents with relapsed ALCL after BFM frontline therapy. 45 Woessmann et al. 45 reported on 77 patients, 24 patients were CD3
þ and 42 patients were CD3
À . An important prognostic factor independent of response to therapy they received was CD3 reactivity. The probability of OS at 3 years for CD3
À vs CD3 þ patients was 62 and 46%, respectively. The relapse rate postAutoSCT was significantly higher in CD3 þ vs CD3 À patients, 16/23 (70%) vs 1/11(9%) (P ¼ 0.001), respectively. High-dose therapy and AutoSCT is effective therapy for CD3 À ALCL but not for CD3 þ tumors. 45 Patients who relapse on therapy vs those who relapse off therapy also had a poor prognosis. The time of relapse was also a significant prognostic indicator. The OS of patients who received high-dose therapy and AutoSCT who relapsed on therapy was 15 ± 6% vs those who relapsed off therapy was 67 ± 9%. 45 Therefore, children with ALCL who either relapse on therapy and/or have CD3
þ ALCL with recurrent disease have a dismal prognosis with high-dose therapy and AutoSCT alone. 45 The BFM group more recently reported on 20 children and adolescents with highrisk early relapse or refractory ALCL who underwent a matched related, matched unrelated or haploidentical myeloablative (MA), total body irradiation containing AlloSCT after the first relapse (n ¼ 9) or multiple relapses (n ¼ 11) (Table 1) . 37 The EFS at 3 years was 75% (Figure 2) , with a transplant-related mortality of 15% and a relapse rate of only 10% (n ¼ 2). 37 The lymphomas were further classified and 17 patients were positive for anaplastic lymphoma kinase expression, and eight were CD3 þ . Donor source did not affect outcome and five patients who received an AlloSCT following AutoSCT survived. 37 These results favor a potential allogeneic graft vs lymphoma (GvLy) response. Further classification and larger trials are needed for this heterogenous ALCL subtype to determine an appropriate risk-stratified treatment approach for pediatric ALCL.
SCT for childhood HD
The management of relapsed and refractory HD remains challenging. Although children with HD achieve an OS rate of 90%, approximately 10-15% fail to attain a CR or relapse. 23, 46 High-risk patients with HD who are refractory to initial therapy, primary induction failure and relapse after primary initial chemotherapy (especially if first CR p12 months duration) have a minimal chance for longterm survival with salvage chemotherapy alone, 47 with a reported 5-to 10-year OS of 20-25%. 48 The length of first remission is a major prognostic factor in attaining a durable second remission with chemotherapy alone in relapsed HD. Studies have shown that patients who relapse after more than 12 months from diagnosis can enter a durable CR2 with standard chemotherapy regimens. 49 The National Cancer Institute compared HD patients who relapsed after a long initial remission to those who relapsed early. They reported a CR2, continued CR and 11-year OS between the two groups of 85, 45, 24 vs 49, 22 and 11%, respectively. These results have been further supported by other studies. 50 In addition, patients with primary or relapsed refractory HD do not respond to standard or salvage chemotherapy regimens, with OS ranging between 0 and 8%. Although there are no pediatric trials, there have been two randomized trials in adult patients with refractory disease or relapse after primary chemotherapy comparing standard dose salvage chemotherapy to high-dose therapy and AutoSCT. 51, 52 Both trials demonstrated significantly improved EFS and longer time to treatment failure in the patients receiving high-dose therapy and AutoSCT vs standard salvage chemotherapy but no significant difference in OS. 51, 52 Stoneham et al. 53 retrospectively compared pediatric patients with relapsed or refractory HD who underwent high-dose therapy and AutoSCT to patients who received conventional salvage chemotherapy ( Table 2 ). The OS did not differ between the two groups, including the subgroup of patients who relapsed early (o1 year). 53 It is, however, difficult to compare these results to other series, due to the non-intensive single modality regimens these patients received compared to the more intensive multiagent regimens used in other countries.
In view of these findings, the standard approach for patients with primary refractory or relapsed HD has historically been high-dose MA chemotherapy followed by AutoSCT. A case-matched comparison of AutoSCT in pediatric (n ¼ 81) and adult (n ¼ 81) patients with HD suggests that pediatric patients have similar EFS and OS compared with adults. 43 There are few reports of AutoSCT in children with HD. There is a wide range of outcomes with an OS and EFS of 43-95 and 31-62%, respectively (Table 2) . 43 Baker et al. 54 reported that the indications for high-dose therapy and AutoSCT in children with relapsed or refractory HD did not differ from those in adults. Multiple prognostic factors, disease status at the time of high-dose therapy and AutoSCT, chemoresponsiveness to salvage chemotherapy, tumor bulk at the time of AutoSCT, remission duration, extranodal relapse and performance status influence outcome in patients with HD following high-dose therapy and AutoSCT. 54, 59 Majhail et al. 60 recently reported in 141 adult patients, median age 30 years, with primary refractory or relapsed HD the probability of PFS at 5 and 10 years was 48 and 45%, respectively, following high-dose therapy and AutoSCT. A multivariate analysis reported that chemoresistant disease, B symptoms at relapse and residual disease at the time of transplant as independent predictors for poor PFS. Patients with zero, one or three of these risk factors had PFS at 5 years of 67, 37 and 9%, respectively. 60 The pediatric literature has supported that extranodal disease at the time of relapse and a large mediastinal mass going into AutoSCT and resistant disease (Figure 3 ) predict for poor OS, EFS and PFS. 54, 55 Additional poor prognostic indicators in pediatric HD include a lactate dehydrogenase (LDH) ratio of more than one, interval from diagnosis to AutoSCT of p15 months and female sex. 43, 54 A high rate of relapse has been demonstrated after highdose therapy and AutoSCT in adult patients with relapsed HD. 61 This is similar to that being reported in the pediatric literature. Lieskovsky et al. 55 also report a high incidence and late failures in their series; 38% of deaths occurred 4-12 years after transplantation and 15% of the patients relapsed after more than 2 years post-AutoSCT (Table 2) . Harris et al. 57 reported the early results of 38 children with relapsed refractory HD who obtained a CR or PR following reinduction therapy and underwent an AutoSCT following cyclophosphamide, carmustine and etoposide conditioning and reported a 43% PFS (Table 2) .
These results suggest that children and adolescents with relapsed/refractory HD who undergo chemotherapy conditioning and AutoSCT have an estimated 20-50% PFS and are still at risk for long-term complications including myelodysplastic syndrome (MDS), AML and breast cancer. Patients who progress following high-dose therapy and AutoSCT have a dismal chance (p10%) of being cured. 61 In addition to the high risk of relapse or progression following MA conditioning þ AutoSCT, there is an increasing incidence in the development of MDS and secondary AML (sAML). Second malignancies are a recognized complication for patients with lymphoma treated with chemotherapy or combined chemotherapy and radiation treatment. 62 The estimated incidence of MDS/sAML in patients with recurrent lymphoma following high-dose therapy and AutoSCT is 4-20% at 5 years. 63 The German Hodgkin's Lymphoma Study Group report a poor outcome in HD patients who develop MDS/sAML, with only a 4% survival rate at 5 years. 64 The prognosis is dismal despite the use of matched related donor AlloSCT in patients with HD who develop MDS/sAML following high-dose therapy and AutoSCT. 64 While MDS/sAML is a significant concern in heavily pretreated high-risk relapsed/ refractory lymphoma patients treated with high-dose therapy and AutoSCT, MDS/sAML is a rare complication after AlloSCT. 65 
Allogeneic graft vs host lymphoma effect
With the use of intensified therapy, children with lymphoma who fail to respond or relapse may not benefit from high-dose therapy and AutoSCT alone and will require different therapeutic approaches. 33, 37 Several studies have suggested that there may be a significant GvLy effect after high-dose therapy and AlloSCT. [65] [66] [67] Jones et al. 67 first demonstrated the evidence of GvLy following high-dose therapy and AlloSCT in patients with lymphoma, the probability of relapse was only 18% in the high-dose therapy and AlloSCT group compared to 46% in the high-dose therapy and AutoSCT subgroup (Figure 4) .
The pediatric literature has further supported this in NHL. O'Leary et al. 36 reported a 56% OS in pediatric patients with newly diagnosed high-risk and relapsed BL (n ¼ 6) or relapsed T-cell LL who received an MA AlloSCT. There were three toxic, non-relapse-related deaths. Relapse occurred in only two patients and occurred early at 2 and 4 months post transplant. 36 Levine et al. 40 reported the results from International Bone Marrow Transplant Registry in 204 patients with LL (median age of 13 years) following high-dose therapy AutoSCT (n ¼ 128) vs AlloSCT (n ¼ 76). Although there was a similar DFS between AlloSCT vs AutoSCT in patients with LL (36 vs 39%), there was a significantly decreased risk of relapse following AlloSCT ( Figure 5) . 40 Most recently, the BFM group reported the results in 20 children with relapsed or progressive ALCL following total body irradiation, cyclophosphamide, VP-16 followed by AlloSCT, a DFS of 75% with a relapse rate of only 10% and transplant-related mortality of 15% (Figure 2) . 37 These data strongly suggest that there is an allogeneic GvLy effect in both childhood and adolescent LL and ALCL.
MA AlloSCT has also demonstrated a reduced relapse rate in adult patients with high-risk relapsed and/or refractory HD. Anderson et al. 66 reported a significantly lower relapse rate in relapsed/refractory HD patients who received a matched sibling AlloSCT compared to AutoSCT, 45 vs 76%, respectively. Akpek et al. 65 more recently confirmed a graft vs HD effect with a lower risk of relapse and development of MDS/sAML in AlloSCT recipients. There was, however, no improvement in OS in the studies reported due to a high transplant-related mortality. These results, however, do suggest a graft vs HD effect. Relapse rates have been consistently less than 40%; however, DFS remains variable (22-55%) due to higher morbidity and mortality associated with high-dose therapy and AlloSCT. 65, 67 The use of non-MA non-toxic regimens to reduce regimen-related morbidity and mortality formally associated with MA AlloSCT but still achieve a GvLy disease effect is currently under investigation. Several adult centers have piloted the use of MA conditioning and AutoSCT followed by non-MA or reduced intensity conditioning and AlloSCT for poor risk adults with lymphoma. 68, 69 These results of high-dose therapy and AutoSCT followed by reduced intensity AlloSCT in very poor risk adults with lymphoma suggest that this approach may also be beneficial in children and adolescents with poor risk HD who are also at risk of late secondary complications. We have previously reported the initial results in 10 children and adolescents with poor risk lymphoma treated with cyclophosphamide, carmustine and etoposide conditioning and AutoSCT followed by busulfan and fludarabine reduced intensity conditioning and AlloSCT with an early 70% EFS and lower risk of relapse (Table 2) . 58 Longer follow up with a larger cohort and a subsequently randomized trial will need to be performed to determine whether this approach reduces the risk of lymphoma relapse and/or reduces the risk of secondary complications compared to standard MA conditioning and AutoSCT in children and adolescents with poor risk lymphoma.
Future investigations following SCT for recurrent/ refractory lymphoma in children will likely focus on reducing minimal residual disease and/or specific and targeted adoptive cellular immunotherapy to reduce disease relapse, which is the major obstacle following SCT. Such approaches may include the use of targeted therapy such as monoclonal antibodies including rituximaab (anti-CD20), epratuzamab (anti-CD22, SGN-30 (anti-CD30), immunotoxin therapy (denileukin diftitox), anti-CD22-calichimiacin, etc. Alternatively, targeted cellular therapies may include EBV-specific cytotoxic T-cell lymphocytes for HD and anti-CD19 or anti-CD20 cytotoxic T-cell lymphocytes or natural killer cells for B-cell NHL. Reducing the burden of lymphoma prior and post-SCT will likely reduce relapse and improve OS following SCT for children with refractory/recurrent lymphoma. 
